Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 11/20 | 0.39 |
| ▸ | CDK9 | P50750 | 11/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118426 | 1.00 | CCNT1 (0.39) | CCNT1CDK9SYKMMP14ADAMTS5 | |
| SCHEMBL7117906 | 0.82 | QDPR (0.39) | MMP14MMP2MMP3NAMPTWNT3A | |
| SCHEMBL7508337 | 0.82 | QDPR (0.39) | MMP14MMP2MMP3NAMPTWNT3A | |
| SCHEMBL7122767 | 0.82 | NAMPT (0.39) | CCNT1CDK9NAMPT | |
| SCHEMBL7126216 | 0.79 | NAMPT (0.49) | NAMPTWNT3A | |
| SCHEMBL7122724 | 0.76 | QDPR (0.40) | NAMPTWNT3A | |
| SCHEMBL7124582 | 0.76 | QDPR (0.40) | NAMPTWNT3A | |
| SCHEMBL7121304 | 0.74 | CCNT1 (0.40) | CCNT1CDK9SYKMMP14ADAMTS5 | |
| SCHEMBL8445301 | 0.73 | CCNT1 (0.38) | CCNT1CDK9SYKMMP14ADAMTS5 | |
| SCHEMBL979793 | 0.68 | QDPR (0.58) | CCNT1CDK9SYKMMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | SYNGENTA LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| US-6350775-B1 | AGAINST GRAMPOSITIVE BACTERIA | ZENECA LIMITED (GB) | 2002-02-26 | — | — | US | disclosed |
| US-6110936-A | A BACTERICIDE TREATING A BACTERIAL INFECTION IN A WARM BLOODED ANIMAL | ZENECA LIMITED (GB) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | CBR1, CBR3, CYP8B1 | CCNT1 1733/4885CDK9 3654/4885SYK 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.